(Reuters) -Charles River Laboratories said on Wednesday it had reached an agreement with activist investor Elliott Investment Management and added four new directors to its board, sending its shares up nearly 24% to $143 before the bell.

The contract research firm, which has Elliott as its largest investor, said it will initiate a comprehensive review of its business, including an examination of various other alternatives to enhance long-term stockholder value.

The investor's exact stake in the company could not be determined.

Elliott's Global Head of Engagement Steven Barg, who previously served on the boards of drug distributor Cardinal Health and contract drug manufacturer Catalent, will join Charles River's board.

The other three independent directors include Rapport Therapeutics CEO Abe Ceesay, former ImmunoGen CEO Mark Enyedy and Rio Tinto Lithium CEO Paul Graves.

Following the new appointments, which will be effective after the annual shareholders meeting on May 20, the board will consist of eleven directors, nine of whom will be independent.

Reuters had reported on the settlement earlier on Wednesday.

Charles River's shares fell last month after the U.S. Food and Drug Administration announced plans to phase out conventional animal testing for monoclonal antibodies and other drugs to focus on more effective, human-relevant methods.

(Reporting by Siddhi Mahatole and Sriparna Roy in Bengaluru; Editing by Shreya Biswas)